2.5600
+0.0200
+(0.79%)
At close: 4:00:00 PM EST
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 1 | 3 | 3 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | 0.00% | 0.00% | 0.00% | 0.00% |
Earnings History
| Currency in USD | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
|---|---|---|---|---|
| EPS Est. | -1 | -0.74 | -0.53 | -0.5 |
| EPS Actual | -0.23 | 0.01 | -0.36 | -0.5 |
| Difference | 0.77 | 0.75 | 0.17 | -0 |
| Surprise % | 77.00% | 101.35% | 31.65% | -0.67% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| CALC | -- | -- | -- | -- |
| S&P 500 | 9.91% | 10.33% | 14.01% | 13.75% |
Upgrades & Downgrades
| Initiated | LUCID CAPITAL MARKETS: Buy | 12/17/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/14/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 11/4/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/13/2024 |
| Maintains | Oppenheimer: Outperform to Outperform | 7/10/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 7/9/2024 |
Related Tickers
EPRX Eupraxia Pharmaceuticals Inc.
2.8957
-3.48%
ANTX AN2 Therapeutics, Inc.
1.1400
-2.56%
AVTE Aerovate Therapeutics, Inc.
2.6200
0.00%
IRBS IR Biosciences Holdings, Inc.
0.0001
0.00%
DNAG DNAPrint Genomics, Inc.
0.0000
-99.00%
VACBF Nykode Therapeutics AS
0.3150
-66.84%
VIAP VIA Pharmaceuticals, Inc.
0.0005
0.00%
HLVX HilleVax, Inc.
1.9700
-1.01%
ENGN enGene Holdings Inc.
6.70
-5.63%
ZBIO Zenas BioPharma, Inc.
8.02
+5.25%